TY - JOUR
T1 - Direct versus calculated LDL cholesterol and C-reactive protein in cardiovascular disease risk assessment in the Framingham Offspring Study
AU - Ikezaki, Hiroaki
AU - Fisher, Virginia A.
AU - Lim, Elise
AU - Ai, Masumi
AU - Liu, Ching Ti
AU - Adrienne Cupples, L.
AU - Nakajima, Katsuyuki
AU - Asztalos, Bela F.
AU - Furusyo, Norihiro
AU - Schaefer, Ernst J.
N1 - Funding Information:
Employment or Leadership: E.J. Schaefer, Boston Heart Diagnostics. Consultant or Advisory Role: V.A. Fisher, statistical consulting; E.J. Schaefer, Denka Seiken Corporation. Stock Ownership: None declared. Honoraria: None declared. Research Funding: H. Ikezaki, the Japan Heart Foundation/Bayer Yakuhin Research Grant Abroad Program, Tokyo, Japan, grant to the Dyslipidemia Foundation of Boston from the Denka Seiken Corporation, Niigata, Japan. Grant to the Dyslipidemia Foundation of Boston from the Denka Seiken Corporation, Niigata, Japan also supported the statistical consultation and analysis of V.A. Fisher, E. Lim, C.-T. Liu, and L.A. Cupples. These latter investigators and the Framingham Offspring Study were supported by grant NHLBI N01-HC 25195 from the National Institutes of Health. B.F. Asztalos and E.J. Schaefer were supported by the US. Department of Agriculture – Agricultural Research Service Specific Cooperative Agreements #58-1950-0-014 and #58-1950-4-003, by Project Grant P50 HL083813-01 and by grant HL117933, both from the National Institutes of Health, as well as by Boston Heart Diagnostics, Framingham, MA. Assay kits for direct LDL-C were kindly provided by the Denka Seiken Corporation, Niigata, Japan, and the Kyowa Medex Corporation, Tokyo, Japan. These companies also provided fellowship support for M. Ai. Expert Testimony: None declared. Patents: None declared.
Publisher Copyright:
© 2019 American Association for Clinical Chemistry.
PY - 2019
Y1 - 2019
N2 - BACKGROUND: Increases in circulating LDL cholesterol (LDL-C) and high-sensitivity C-reactive protein (hsCRP) concentrations are significant risk factors for cardiovascular disease (CVD). We assessed direct LDL-C and hsCRP concentrations compared to standard risk factors in the Framingham Offspring Study. METHODS: We used stored frozen plasma samples (-80 °C) obtained after an overnight fast from 3147 male and female participants (mean age, 58 years) free of CVD at cycle 6 of the Framingham Offspring Study. Overall, 677 participants (21.5%) had a CVD end point over a median of 16.0 years of follow-up. Total cholesterol (TC), triglyceride (TG), HDL cholesterol (HDL-C), direct LDL-C (Denka Seiken and Kyowa Medex methods), and hsCRP (Dade Behring method) concentrations were measured by automated analysis. LDL-C was also calculated by both the Friedewald and Martin methods. RESULTS: Considering all CVD outcomes on univariate analysis, significant factors included standard risk factors (age, hypertension, HDL-C, hypertension treatment, sex, diabetes, smoking, and TC concentration) and nonstandard risk factors (non-HDL-C, direct LDL-C and calculated LDL-C, TG, and hsCRP concentrations). On multivariate analysis, only the Denka Seiken direct LDL-C and the Dade Behring hsCRP were still significant on Cox regression analysis and improved the net risk reclassification index, but with modest effects. Discordance analysis confirmed the benefit of the Denka Seiken direct LDL-C method for prospective hard CVD endpoints (new-onset myocardial infarction, stroke, and/or CVD death). CONCLUSIONS: Our data indicate that the Denka Seiken direct LDL-C and Dade Behring hsCRP measurements add significant, but modest, information about CVD risk, compared to standard risk factors and/or calculated LDL-C.
AB - BACKGROUND: Increases in circulating LDL cholesterol (LDL-C) and high-sensitivity C-reactive protein (hsCRP) concentrations are significant risk factors for cardiovascular disease (CVD). We assessed direct LDL-C and hsCRP concentrations compared to standard risk factors in the Framingham Offspring Study. METHODS: We used stored frozen plasma samples (-80 °C) obtained after an overnight fast from 3147 male and female participants (mean age, 58 years) free of CVD at cycle 6 of the Framingham Offspring Study. Overall, 677 participants (21.5%) had a CVD end point over a median of 16.0 years of follow-up. Total cholesterol (TC), triglyceride (TG), HDL cholesterol (HDL-C), direct LDL-C (Denka Seiken and Kyowa Medex methods), and hsCRP (Dade Behring method) concentrations were measured by automated analysis. LDL-C was also calculated by both the Friedewald and Martin methods. RESULTS: Considering all CVD outcomes on univariate analysis, significant factors included standard risk factors (age, hypertension, HDL-C, hypertension treatment, sex, diabetes, smoking, and TC concentration) and nonstandard risk factors (non-HDL-C, direct LDL-C and calculated LDL-C, TG, and hsCRP concentrations). On multivariate analysis, only the Denka Seiken direct LDL-C and the Dade Behring hsCRP were still significant on Cox regression analysis and improved the net risk reclassification index, but with modest effects. Discordance analysis confirmed the benefit of the Denka Seiken direct LDL-C method for prospective hard CVD endpoints (new-onset myocardial infarction, stroke, and/or CVD death). CONCLUSIONS: Our data indicate that the Denka Seiken direct LDL-C and Dade Behring hsCRP measurements add significant, but modest, information about CVD risk, compared to standard risk factors and/or calculated LDL-C.
UR - http://www.scopus.com/inward/record.url?scp=85071785893&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071785893&partnerID=8YFLogxK
U2 - 10.1373/clinchem.2019.304600
DO - 10.1373/clinchem.2019.304600
M3 - Article
C2 - 31239251
AN - SCOPUS:85071785893
SN - 0009-9147
VL - 65
SP - 1102
EP - 1114
JO - Clinical Chemistry
JF - Clinical Chemistry
IS - 9
ER -